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Abstract: This study aims to consider the microbial distribution in oral disease, as well as gene
analysis and expression, in elucidating: 1, the fundamental underpinnings of oral disease, and
2, the potential relationship between oral diseases and systemic health. A key focus is identifying
the microbiota associated with oral disease manifestations characterized by both conventional
microbiological and molecular methods. Variations in the observed microbial populations
characterized by conventional and molecular approaches have been identified for caries, periodontitis,
peri-implantitis, and stomatitis. The discovery of therapeutic approaches for oral disease will require
comprehensive microbial and genomic analysis. This study evaluated the current state of the relevant
microbial and genomic information for several prevalent oral diseases.
Keywords: oral disease; systemic health; oral microbiota; microarrays
1. Introduction
Over the past 30 years, research has begun to elucidate the etiology of oral diseases.
A key contributor to oral disease is the complex oral microbiome. The oral cavity is home to
about 700 microbial species, many of which interact with host factors. Oral disease resulting from
microbe–host interaction can cause systemic diseases, some of which may be lethal.
The composition of the oral microbiota in dentate individuals differs significantly from that of
edentulous individuals [1]. The oral microbiome of dentate individuals contains greater proportions of
anaerobes and spirochetes, while the prosthetic dentures of edentate patients harbor a larger percentage
of aerobic organisms, as well as yeast and lactobacilli [2,3]. This dissimilarity must be considered
when examining a potential oral and systemic connection. Figure S1 summarizes the similarities and
differences of microbial communities present in dentate and edentulous populations [1].
The study of genomes, both human and microbial, can provide insight into the etiology of
disease, as well as help elucidate potential approaches for therapeutic intervention. DNA microarrays,
also referred to as gene chips, allow for massively parallel, rapid screening of thousands of genes.
The methodology allows for the identification of genes that are expressed differentially. Gene chips
show the modulation of mRNA expression levels, suppression of gene expression, and activation of
gene expression. This technology allows for large-scale genomic analysis between patients with and
without a given disease.
The objectives of this paper include: (i) to provide a perspective for the role of microbes in
several oral diseases; (ii) to identify differences between microbes detected by classical microbiological
approaches as compared to molecular analyses; and (iii) to provide a genomic perspective on the
relationship between oral and systemic health.
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2. Caries
Dental caries is one of the most widespread chronic diseases [4]. Current epidemiological studies
indicate a marked increase in the prevalence of dental decay among all age groups [5]. Dental caries
is a polymicrobial infection that results from an imbalance of the dynamic metabolic process in the
dental biofilm [6]. The ultimate harm to the teeth is not apparent until the mineralization balance in
the supragingival biofilm is disturbed, affecting homeostasis in the biofilm [7]. Classical experimental
techniques have provided significant information on the microorganisms associated with dental caries.
Tooth decay is initially activated by early colonizers such as Streptococcus oralis, followed by adherence
of Streptococcus sobrinus and Stretococcus mutans [8].
More recently, the Human Oral Microbe Identification Microarray (HOMIM) has been used
to provide a more comprehensive description of the biofilm composition associated with the oral
cavity. It can detect pathogens regardless of whether they can be cultivated or not [6,8]. This new
metagenomic approach may also be useful to assess the dynamic process of the metabolic activity of
biofilms. Microarrays hold high promise for advancements in oral biology. They are specifically useful
for the diagnosis, prevention, and monitoring of microorganisms in the oral cavity, which should lead
to better management of patients’ oral health [9].
One of the areas in clinical dentistry where microarrays have proved to be very effective is
the analysis of the oral microbiota in pediatric patients between the age of three months and three
years [10]. Using gene chip analysis, the relationship between the microorganisms and the presence
or absence of caries can be assessed. Microarray analysis has shown that many of the bacteria that
colonize the oral cavity at three months of age continue to be present at three years of age. A few of the
early bacteria cease to exist as the baby matures, and correspondingly, new pathogens start colonizing
at age three for more than 50% of children [10]. Although the microbiota composition at three months
of age is unrelated to caries development at a later age, several pathogens present in the oral biofilms
of three-year-olds can be linked to caries [10].
DNA sequencing has also been used to examine the bacterial community associated with caries.
The 454 sequencing technology (454 Life Sciences, Branford, CT, USA) was used to evaluate microbial
diversity influenced by the pH of cavitated lesions [11]. pH within a dentinal cavitated lesion was
found to significantly affect the microbial population of 42% of the caries-associated bacteria.
Interestingly, bacterial culture methodologies continue to provide information on the bacterial
composition associated with caries. An anaerobic culture of bacteria associated with caries has been very
valuable in elucidating the bacterial population. Using rich non-selective media and anaerobic incubation
has resulted in the improved detection of Actinobacteria as compared to PCR and cloning/sequencing
analysis [12]. Table 1 summarizes the representative bacteria associated with dental caries.
Table 1. Microbiota associated with caries.














Saliva is a biological fluid secreted by the salivary glands. Saliva contains bacteria originating
from the surfaces of various intraoral surfaces, including teeth, gingival crevices, tongue and buccal
mucosa [13]. Bacterial species prevalent in saliva are summarized in Table 2.
Saliva is also a rich source of proteins, mRNA, miRNA (non-coding RNA), and antibodies [14–19].
It therefore has immense diagnostic potential, both for identifying individuals with a given disease
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and for tracking patients’ disease progression and treatment response. An obvious advantage of this
strategy is that the collection of saliva is a non-invasive procedure.








Microarrays have proven to be excellent experimental platforms to analyze saliva [14,17].
The results provided by microarrays are rapid and remarkably precise, two factors that are key
in diagnostics. Salivary analysis by microarrays has been used to identify and track numerous systemic
diseases. For example, fiber microarrays have been used to demonstrate the altered salivary protein
profile of patients with asthma and cystic fibrosis [20], whereas a microsphere-based array could not
identify a significant alteration. Investigators have even developed an effective discriminatory salivary
test, in which microarray detection of the downregulation of five salivary mRNA biomarkers reliably
indicates the presence of ovarian cancer [21].
Many other diseases have been shown to impact the saliva’s contents. While microarrays have
not yet been used as a diagnostic tool for these clinical states, there is certainly potential for the
development of such procedures. There are numerous diseases whose impact has been illustrated:
19 genes are differentially expressed in the saliva of Sjogren’s syndrome patients [22], and autoantigens
in the saliva differ according to the subtype of systemic lupus erythematous [23]. The blood-borne
pathogens, human immunodeficiency virus [24] and hepatitis C virus antibodies can be found in
salivary concentrations that correlate to the systemic viral load [25]. With respect to metabolic diseases,
65 proteins are differentially expressed in the saliva of patients with type II diabetes mellitus [26].
There is potential for advancement in cancer salivary diagnostics as well; proteins, mRNA and miRNA
have been shown to have distinct patterns in patients with breast cancer [27], head and neck squamous
cell carcinoma [28], lung cancer [29], oral squamous cell carcinoma [30], and resectable pancreatic
cancer [31] (Table 3).
Table 3. Cancer salivary biomarkers.
Cancer Up-Regulation Down-Regulation Reference
Breast Cancer
Vascular Endothelial Growth Factor (VEGF)
































Cancer miRNA-940 miRNA-3679-5p [31]
CCNI: Cyclin I; FGF19: Fibroblast Growth Factor 19; FRS2: Fibroblast Growth Factor Receptor Substrate 2; GREB1:
Growth Regulation by Estrogen in Breast Cancer 1.
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4. Gingivitis and Periodontitis
The composition of the oral microbiota has been investigated for well over half a century. With the
advent of molecular diagnostic assays including DNA probes and PCR, as well as immunoassays
designed to characterize the association between the subgingival microbiota and the levels of
biomarkers released by tissues and cells measured in gingival crevicular fluid (GCF), significant
progress has been made in elucidating the composition of the subgingival microbiota. The role
of five main microbial complexes in the gingival biofilm was characterized and described using
a checkerboard DNA–DNA hybridization [32]. Using cloning and Sanger sequencing, as well as
next-generation sequencing techniques, suggested that cultivatable as well as not-yet-cultivatable
microbial species are involved in the etiology of periodontitis [33,34]. Based upon current information,
it appears that periodontal disease is the result of infection, with a relatively small number of interacting
species. Periodontal microbiota identified by classical microbiology methods as well as molecular
approaches are summarized in Table 4. A systemic review was reported that showed the association
of 17 species/phylotypes from the Bacteria domain, the Candidatus Saccharibacteria phylum, and the
Archaea domain with the etiology of periodontitis [35].
Table 4. Microbiota associated with periodontitis.








In clinical practice, microarrays can be used to detect and quantify the specific pathogens
responsible for periodontitis [37]. They can also be utilized to identify whether the pathogens are
the ones more likely to be associated with refractory periodontitis, and to assess the efficacy of
periodontal therapy [38]. Kinney et al. [39] demonstrated that by examining the salivary concentrations
of pathogens, matrix metalloproteinase-8 and -9 (MMP-8, MMP-9), calprotectin, osteoprotegerin
(OPG), tumor necrosis factor (TNFα), interferon (IFN), and numerous interleukins (ILs), one can
examine the progression or non-progression of periodontal disease. Furthermore, a number of these
salivary solutes can be used predictively: high concentrations of pathogens Fusobacterium nucleatum,
Campylobacter rectus and Prevotella intermedia predict disease progression, while low levels of MMP-8,
MMP-9, OPG and IL-1β predict stability [39].
From a research perspective, microarrays are valuable tools for gaining further understanding
of the pathophysiology of periodontitis. For example, they have been used to demonstrate the
involvement of long non-coding RNAs (IncRNAs) in the pathogenesis, with the upregulation of
4313 and downregulation of 4612 lncRNAs in chronic periodontitis tissue [40], and to establish
that both chronic and aggressive periodontitis have similar gene expression profiles, with limited
differences in the gingival transcription patterns [41]. Interestingly, Schaefer [42] used microarray
analysis to reveal that certain genetic variations thought to bear connection to periodontitis do not,
in fact, predispose patients to development of this disease [42]. Microarrays have even been used to
identify an apoptotic pathway as a potential anti-periodontitis pharmacological target [43].
Microarrays are often used in comparative studies to determine altered levels of bacterial
pathogens, or the expression of genes in patients with and without periodontitis. Belstrom et al.
demonstrated that certain bacterial taxa are upregulated only in the saliva of periodontitis patients,
rather than the saliva of patients with good oral health [44]. MicroRNA (miRNA) has been a large focus
in this subfield; Xie discovered that in comparison to healthy gingival tissue, inflamed gingival tissue
caused the upregulation of 91 miRNAs and downregulation of 34 miRNAs, all over two-fold [45].
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Similarly, Lee showed that six miRNAs are upregulated in periodontitis [46]. It has been suggested
that salivary miRNAs will comprise the next generation of diagnostic periodontitis tests, but it will be
necessary to first develop standardized tests and protocols [47].
5. Peri-Implantitis
Reconstructive dentistry today is largely facilitated by dental implants, as compared to fixed or
removable partial dentures. During the past decade, the rate of growth for osseointegrated dental
implants in Americans has been estimated at approximately 500,000 per year [48]. The increase in the
number of implants has also given rise to a corresponding increase in clinical problems associated with
the implants. Two diseases, peri-implant mucositis and peri-implantitis, have emerged as diseases
associated with dental implants. Peri-implant mucositis is similar to gingivitis; it is characterized by
inflammation of the mucosa without a corresponding bone loss. Peri-implantitis is characterized as a
more severe inflammatory lesion, with a loss of supporting bone around an implant. Like gingivitis
and periodontitis, peri-mucositis and peri-implantitis are also initiated with microbial infections.
Peri-implantitis can result in a loss of the implant as well as infection of other implants or the remaining
natural teeth. Peri-implantitis is asymptomatic, since pain is infrequent. As a consequence, patients do
not recognize that a problem exists until the onset of implant mobility. Of all implant recipients, the
prevalence of peri-implantitis has been estimated at 28–56% [48].
Peri-implantitis is a polymicrobial infection [48]. There are relatively few studies that have used
molecular approaches to characterize the peri-mucositis and peri-implantitis microbiota [49]. The use
of 16S-based sequencing suggests that the peri-implant microbiome may be distinct from that of
the periodontal microbiome. To date, no deep metagenomic sequencing analyses of peri-implantitis
samples have been reported. Table 5 summarizes the microbiota associated with peri-implantitis, as
identified by both conventional as well as molecular methodologies [50,51].
Table 5. Microbiota associated with peri-implantitis.




















Limited studies focused on the genomic and gene expression profiles for peri-implantitis have
been reported [52]. Peri-implant healing has been associated with the differential expression of several
genes, including cytokines, growth factors, transcription factors and secretory products.
6. Stomatitis
In denture stomatitis (DS), the denture is a major reservoir of many microbes, especially
Candida albicans, a chronic source of infection. The denture surface provides a matrix that allows
for the development of a pathogenic yeast biofilm. The surface under a denture is more acidic and
less open to the oral mucosal saliva. This provides for an ideal environment for C. albicans enzymatic
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activity, which leads to C. albicans biofilm colonization and resistance. C. albicans biofilms are the
reservoirs for infection; they are enclosed within their own extracellular matrix (ECM) and attached to
the surface.
The biofilm composition and structure protects the fungi from the environment, physical and
chemical stress agents, and provides resistance to antifungal agents as well. Indeed, the biofilm is up
to 1000-fold more resistant to antifungal agents than planktonic free-floating cells [53]. Planktonic cells
are thin, and have to undergo irreversible genetic changes to provide resistance. However, biofilms are
200–300 nm thick, and are able to persist due to their physical presence in a phase-specific manner,
regardless of genetic alteration. The biofilm resistance is correlated with efflux pumps that develop
during the intermediate phases of biofilm formation and extracellular matrix (ECM) production.
Table 6 lists the microbes associated with stomatitis that have been identified by conventional
microbial methodologies. The microbes related to stomatitis that have been identified by molecular
analytical approaches are catalogued in Figure S1. The contribution of molecular biology to the
elucidation of stomatitis-related microbes is readily apparent upon comparing the microbial population
identified by conventional methods with those characterized by molecular approaches.







To better understand the molecular underpinnings of DS, microarray technologies have been
used to assess gene expression variability, from an early stage of biofilm growth to the maturity
associated with DS. The genomic composition of the mucosa of healthy denture wearers has been
compared to the mucosa of denture wearers with DS, and it was found that more than 3000 genes
are subjected to transcriptional expression changes in the diseased state as compared to the healthy
state [55]. Among those genes differentially expressed, 71 genes were downregulated. These genes
code for neutrophil, lymphocyte, monocyte, keratins, and epithelial adhesion molecules, all of which
mediate an innate response and the release of inflammatory mediators in DS. In contrast, 235 genes
were upregulated in response to hyphae that were inserted by Candida albicans biofilm into underlying
epithelial layers.
All of the upregulated genes increase the ability of C. albicans to bind and penetrate the oral
epithelial mucosa, and so lead to the increase in inflammatory response. Knowing what genes are
expressed differently, and whether they are upregulated or downregulated, and also knowing at what
phase of biofilm formation these changes of gene expression are developed, provides an understanding
as to why biofilms are mostly antifungal resistant.
7. Conclusions
A systems approach has been presented to catalogue the microbes involved in several oral diseases.
Both conventional microbiology as well as new molecular analytical methodologies are needed to
comprehensively define the representative microbial populations in oral disease. Discovery of the
right therapeutic interventions will require microbiology classification, DNA information, clinical
information (medical records) and lifestyle information. The hope is that analyzing the microbiota, the
microbial genomes, and the host human genome, alongside performing functional genomic analysis,
will reveal critical pathways associated with the initiation and progression of oral disease, and provide
candidate targets for drug therapies.
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Supplementary Materials: The following are available online at www.mdpi.com/2571-5135/6/1/2/s1, Figure S1:
Microbial flora present in dentate and edentulous populations.
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